Bridgebio asks FDA to approve potential 1st treatment for LGMD2i

Bridgebio Pharma has submitted an application asking the U.S. Food and Drug Administration (FDA) to approve its experimental oral therapy, BBP-418, to treat limb-girdle muscular dystrophy type 2i (LGMD2i).

Click here to read the full article.